Projets novateurs réalisés

Internship

Real Estate Feasibility on Green/Energy Efficient Community: Case on Waßmanndorf near Berlin Airport

In vitro characterisation of condensate formation in human Neurogenin-3

Towards High Precision Spectroscopy on Antihydrogen

The matter and antimatter asymmetry that is observed within our universe is one of the more prevasive questions remaining in modern physics today. While theoretically appearing in equal amounts, physicists observe a distinct lack of antimatter in our universe, the nature of which is unknown. The Antihydrogen Laser Physics Apparatus (ALPHA) Collaboration is an international collaboration based at the European Organization for Nuclear Research (CERN) in Geneva, Switzerland, that is focused on the study of the antihydrogen atom in search for possible deviations that may have resulted in the observed matter-antimatter asymmetry we see today. Through detailed studies and comparisons between the antihydrogen atom with the hydrogen atom, which is one of the most well-known atoms in atomic physics, we are searching for possible discrepancies in the constitution and interactions within the two atoms. The objective of the proposed project is to aid in the improvement and development of various parts of the infrastructure at the ALPHA Collaboration in order to perform high precision spectroscopy measurements. Our aim is to improve these spectroscopic measurements through the fine control of the atoms quantum states and energies with the use of microwaves and advanced magnetic field measurements.

Determining Chemical exchange and J-coupling constants in SABRE Hyperpolarization

Operational and Strategic Plan Development of an Accelerator in the Technological Innovation for Health Care sector1.3. Academic Discipline:[ Y ]Business

The proposed project is to research the steps needed to take in order to build and sustain an accelerator/incubator in the health care sector, which will provide core processes and steps to the partner organization. The following steps would be undertaken:

o Analysis of other successful incubators/accelerators in the health care space.

o Partnership wish list.

o Strategic plan

o Operational management plan

o Benchmark and KPIs for continuous analysis and performance evaluations

The influence of forest floor changes on the success and composition of tree regeneration

Working in an Industrial Fog Computing Environment

L2M QC Spring 2025 | Recapitulating the Tumor Immune Microenvironment and Stromal Interactions with Customizable Living 3D Bioprinted Human Solid Tumor Models for High-Throughput Preclinical Oncology and Translational Drug Development

We are developing a library/biobank of in vitro 3D bioprinted living tumor models to accelerate cancer drug development and bridge the translational gap. By incorporating human cells into organ-specific proprietary 3D bioprintable hydrogels we replicate the biochemical and physical properties of the tumor microenvironment with a high degree of complexity using only bio-derived materials. By leveraging 3D bioprinting, we achieve precise spatial control of our tumor constructions to engineer truly biomimetic structures that grow into human tissues to provide high-throughput testing of new therapeutic candidates. This system can be augmented with computer vision analysis and provides the potential for machine-learning integration with biomarker and mechanism of action analysis. The main objective of this project is for the intern to conduct an in-depth market study in the pharmaceutical sector with particular emphasis on large and small biopharmaceutical developers with oncology products in the pipeline for the potential applications of our innovative humanized 3D bioprinted tumor models. Through this project the intern will interact with key industry stakeholders to assess the market potential. The insights from this exercise will be used to present a potential business model and a thorough market analysis to determine the path to follow for the commercial development of the project.

L2M QC Spring 2025 | PROSHIELD – Proactive AI Cybersecurity Defense Platform

In light of the recent concerning growth of cyberattacks in pace, scale, and sophistication empowered by contemporary Artificial Intelligence (AI) techniques with multiple complex hacking and penetration tools, Small and Medium Businesses (SMBs) suffer continuous and serious technical, financial, and societal hits as severe damages of these attacks. This surge in cyberattacks boosted by AI overpowered the existing defensive techniques such as signature-based intrusion detection, firewalls, antivirus software, and even Machine Learning (ML)-based solutions. The painful proof is that the average cost per data breach is estimated at CA$6.32 million paid by Canadian organizations (IBM Newsroom, 2024).
ProShield is a cutting-edge cybersecurity company that leverages advanced generative artificial intelligence techniques under the large language models (LLMs) architecture and their Natural Language Understanding capabilities to provide state-of-the-art cyber threat detection solutions under the concept of LLM-as-a-Service. Our services are designed to match the sophistication of AI-driven attacks leveraging red teaming-backed methods, offering tailored, efficient, and adaptive vulnerability exploration and their respective defense strategies for businesses of all sizes. ProShield offers multiple service packages, allowing companies to choose the protection they need based on their specific risk profiles and budgets.

L2M QC Spring 2025 | Instant Air Risk Detection for Health and Climate (Patholyzer)

Rapid and accurate detection and classification of pathogens (viruses vs. bacteria) is a global challenge affecting healthcare, public health, and environmental safety. Current methods like PCR and CRISPR are accurate but slow, expensive, and require centralized labs and trained personnel. Rapid antigen tests are faster but lack accuracy and cannot differentiate between bacterial and viral infections, leading to misdiagnoses and increased antibiotic resistance.
Patholyzer is an AI-powered, laser-camera-coupled device that detects and classifies bacteria and viruses in real-time (within 32 milliseconds) without sample preparation or lab infrastructure. Built on Nano-Digital Inline Holography Microscopy (Nano-DIHM), a patented and software-copyrighted technology, Patholyzer is a groundbreaking tool for pathogen detection. This innovation has wide-ranging applications, including infection control in hospitals, disease surveillance by public health agencies, bioaerosol monitoring, and environmental pathogen tracking by Research labs. By enabling faster, on-site detection, Patholyzer enhances outbreak prevention and reduces antimicrobial resistance (AMR).
Through the Lab2Market (L2M) program, we aim to refine Patholyzer’s go-to-market strategy, validate customer demand, establish industry partnerships, and secure regulatory approvals. This project will accelerate Patholyzer’s transition from research to commercialization, positioning Canada as a leader in AI-driven diagnostics and public health innovation.

L2M QC Spring 2025 | Sparx Genomics

Leveraging large-scale genetic data for identifying novel therapeutic targets.

Developing a new drug takes an average of twelve years and costs over a billion dollars. This exorbitant cost is largely due to the high failure rate in drug development. In fact, more than 90% of drugs tested in humans will never reach the market. In most cases, the drug simply does not have the expected therapeutic effect. Thus, the significant effect observed in animal models such as mice fails to translate to humans.
To reduce the high failure rate in drug development, Sparx Genomics has developed the GET (Genetic Evidence for Target) platform, which consolidates public domain data on over 30 million genetic variants and more than 10,000 human traits and diseases. Sparx Genomics has also developed the YETI (Yardstick for Efficient Target Identification) algorithm, which helps identify the most effective and safest therapeutic targets.
By identifying molecules with a higher probability of playing a causal role in disease, Sparx Genomics could help reduce the risk of failure. Ultimately, this reduction in failure risk translates into lower drug development costs, which could decrease by as much as $130 million per approved drug.
Sparx Genomics aims to develop therapeutic candidates validated by its YETI algorithm. It also seeks to partner with other drug development companies to help them focus their efforts on the most promising molecules.
Sparx’s mission is to turn genetic data into therapeutic successes. By reducing drug development costs, Sparx contributes to providing better and more affordable new treatments to all Quebecers, Canadians, and citizens worldwide.